Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Amrif General Information
Amrif is developing RESCAP, a proprietary oral enzyme supplement based on alkaline phosphatase. Preclinical studies in animal models have shown that supplementation with this enzyme can restore gut barrier function and significantly increase lifespan and healthspan. The company targets age-related and chronic inflammatory diseases but has not yet reported human clinical trial results.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Wageningen*, Gelderland*
Netherlands
Netherlands
Drug Pipeline
RESCAP
Pre-clinicalKey Partnerships
Amrif Funding
No funding data available
To view Amrif's complete valuation and funding history, request access »